cagrilintide/semaglutide New in the August 14, 2025, issue of NEJM: ⁣ ⁣ Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial)⁣ ⁣ Cagrilintide– Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial)⁣ ⁣ Cagrilintide and Semaglutide: CagriSema Weight

By staying informed and proactive, you can take control of your health and well-being

Cancer interaction : Could enhanced cell proliferation affect tumor growth in predisposed individuals

Osteoblasts produce bone

investigators focused exclusively on the tissue-repair pair use the smaller two-component blend

Advantage: Convenient, familiar, non-invasive Challenge: Peptides face proteolytic degradation in the stomach and small intestine Bioavailability: Estimated at approximately 38% based on comparative pharmacology (see below) Transdermal (Patch) Some researchers have explored transdermal patches to deliver peptides: Advantage: Avoids first-pass metabolism and GI degradation Challenge: Intact skin is a strong barrier to peptide penetration Feasibility: Not commonly available commercially